text: An early-stage human clinical trial for an Ebola vaccine is likely to begin as early as September, 2014, the US National Institutes of Health has disclosed
  Though not the first human vaccine trial for the virus, the study comes after mounting pressure from health organisations to allow experimental treatments to be used on people at high risk of developing the disease.
  The vaccine, developed by the National Institute of Allergy and Infectious Diseases, NIAID, Vaccine Research Center, contains no infectious Ebola virus material. Instead, it is a chimpanzee adenovirus vector vaccine containing an insert of two Ebola genes.
  Adenovirus vectors are attractive delivery models for vaccine candidates because the virus can be easy manipulated. As a nonreplicating viral vector, the vaccine works by entering a cell and delivering the new genetic material. The new gene inserts cause a protein to become expressed, which in turn elicits Dr. Anthony Fauci, said the NIH’s Ebola vaccine has been studied in monkeys.”If it is successful, it will take until mid- to late-2015 before a limited number of vaccine doses would be ready to administer to health care workers, he said.
  The clinical trial participants won’t be exposed to the Ebola virus, Fauci said. Instead, they’ll stay in the United States, where they’ll be given a dose of the vaccine and tested to see if their antibody levels match the levels shown in monkey studies to protect the monkeys from Ebola. Scientists will also be watching for adverse reactions to the vaccine to make sure it is safe.
  Meanwhile, health campaigners have petitionedo the US Food and Drug Administration, FDA, asking it to speed up the authorisation of a new drug called TKM-Ebola which is widely believed to be a cure for EVD. TKM-Ebola is a promising vaccine on trial.
  In the petition entitled “Fast track Drug and vaccine research for Ebola Hemorrhagic fever”, the petitioners said given that at least one patient has transferred the disease from Liberia to Nigeria by air travel, the possibility of a global pandemic becomes increasingly likely.
  Comments expressed here do not reflect the opinions of Vanguard newspapers or any employee thereof.